Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medartis Holding AG (MED.SW)
CHF92.10
+2.20 (+2.45%)
CH SIX Healthcare Medical - Devices
Address
Hochbergerstrasse 60E 4057
Basel, CH
Basel, CH
CEO
Matthias Schupp
Website
medartis.com
IPO
2018-03-23
ISIN CH0386200239
Also trades on
Other OTC · MDRSF (USD)
Swiss Exchange · MED.SW (CHF)
Description
Medartis Holding AG is a global medical technology firm that develops, manufactures, and distributes implantable solutions. These advanced medical devices are utilized worldwide for the surgical stabilization of bone fractures in both the upper and lower extremities, in addition to addressing complex cranio-maxillofacial surgical needs. The company's portfolio features osteosynthesis instruments, marketed under the APTUS and MODUS brands, specifically designed for various body regions including the hand, wrist, elbow, shoulder, foot, and ankle, as well as for facial and skull procedures involving the mandible, midface, orthognathic structures, and cranium. Medartis serves a diverse clientele comprising surgeons, hospitals, medical centers, and group purchasing organizations. The company, founded in 1997, is headquartered in Basel, Switzerland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CHF92.10
+2.20 (+2.45%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7.5K
Beta
1.18
Float Shares
4.39M
Free Float %
35.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.13% | +2.23% | +1.17% | -15.43% | -10.06% | -7.60% | -2.14% | +8.06% | -6.49% | +25.56% | +25.56% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
92.10
DCF (Levered)
65.53
-28.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.19
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+19.8% ★ Q4'25: +34.4% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+139.3% ★ Q4'25: +558.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+7.0% ★ Q4'25: +7.9% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+7.5% ★ Q4'25: -5.6% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+3.7% ★ Q4'25: -7.1% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+0.3% Q4'25: +0.7% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×3.45× Q4'25: 7.03× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
121.32M
est: 121.75M (-0.3%)
|
130.14M
est: 129.41M (+0.6%)
|
127.65M
est: 124.55M (+2.5%)
|
159.88M
est: 148.76M (+7.5%)
|
182.82M
est: 186.21M (-1.8%)
|
212.01M
est: 220.28M (-3.8%)
|
224.83M
est: 234.28M (-4.0%)
|
269.26M
est: 267.50M (+0.7%)
|
328.81M
318.20M – 334.66M
+22.9% YoY
|
384.46M
375.59M – 394.37M
+16.9% YoY
|
449.31M
447.00M – 451.62M
+16.9% YoY
|
538.41M
523.69M – 550.30M
+19.8% YoY
|
| EBITDA |
11.25M
est: 14.83M (-24.1%)
|
20.34M
est: 8.57M (+137.4%)
|
13.96M
est: 12.51M (+11.6%)
|
26.10M
est: 14.87M (+75.5%)
|
15.64M
est: 17.05M (-8.3%)
|
24.69M
est: 43.72M (-43.5%)
|
30.18M
est: 45.86M (-34.2%)
|
45.72M
est: 53.10M (-13.9%)
|
65.27M
63.16M – 66.43M
+22.9% YoY
|
76.31M
74.55M – 78.28M
+16.9% YoY
|
89.18M
88.72M – 89.64M
+16.9% YoY
|
106.87M
103.95M – 109.23M
+19.8% YoY
|
| EBIT |
2.90M
est: 2.95M (-1.6%)
|
7.35M
est: 6.43M (+14.5%)
|
-1.92M
est: 6.65M (-129.0%)
|
9.72M
est: 7.90M (+23.0%)
|
-2.47M
est: 9.06M (-127.3%)
|
11.44M
est: 24.59M (-53.5%)
|
7.88M
est: 25.79M (-69.4%)
|
20.27M
est: 29.86M (-32.1%)
|
36.70M
35.52M – 37.35M
+22.9% YoY
|
42.91M
41.92M – 44.02M
+16.9% YoY
|
50.15M
49.89M – 50.41M
+16.9% YoY
|
60.10M
58.45M – 61.42M
+19.8% YoY
|
| Net Income |
4.20M
est: 5.12M (-17.9%)
|
2.15M
est: 4.46M (-51.8%)
|
-943.6K
est: 1.94M (-148.6%)
|
6.84M
est: 2.31M (+196.5%)
|
-5.78M
est: -6.63M (+12.8%)
|
619.0K
est: 3.87M (-84.0%)
|
3.53M
est: 10.90M (-67.6%)
|
8.35M
est: 8.35M (+0.0%)
|
18.04M
16.76M – 20.24M
+116.1% YoY
|
28.07M
27.30M – 28.84M
+55.6% YoY
|
37.59M
36.47M – 42.69M
+33.9% YoY
|
57.30M
55.26M – 58.94M
+52.4% YoY
|
| SGA |
81.73M
est: 79.50M (+2.8%)
|
89.37M
est: 80.71M (+10.7%)
|
87.22M
est: 72.55M (+20.2%)
|
103.05M
est: 86.25M (+19.5%)
|
126.03M
est: 98.87M (+27.5%)
|
131.99M
est: 141.99M (-7.0%)
|
140.51M
est: 134.08M (+4.8%)
|
172.72M
est: 172.42M (+0.2%)
|
211.94M
205.10M – 215.71M
+22.9% YoY
|
247.81M
242.09M – 254.20M
+16.9% YoY
|
289.61M
288.12M – 291.10M
+16.9% YoY
|
347.04M
337.56M – 354.71M
+19.8% YoY
|
| EPS |
0.40
est: 0.41 (-3.1%)
|
0.18
est: 0.00 (+7,393.4%)
|
-0.08
est: -0.30 (+73.3%)
|
0.58
est: 0.68 (-14.1%)
|
-0.49
est: -0.13 (-276.9%)
|
0.05
est: 0.31 (-83.8%)
|
0.28
est: 0.88 (-68.1%)
|
0.67
est: 0.56 (+18.7%)
|
1.48
1.35 – 1.63
+162.7% YoY
|
2.24
2.19 – 2.32
+51.1% YoY
|
3.13
2.93 – 3.43
+39.8% YoY
|
4.60
4.44 – 4.74
+47.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
75.60M
OE per share TTM
6.00
Owner's Yield
7.82%
Maintenance CapEx ratio
26.03%
Maint CapEx / Avg PPE
40.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 21 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.03% | 1.98M | 0.10% |
| 2 | Schwab International Small-Cap Equity ETF SCHC | 0.02% | 1.02M | 0.06% |
| 3 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.59M | 0.06% |
| 4 | Vanguard FTSE Europe Shares ETF VEQ.AX | 0.00% | 12.6K | 0.35% |
| 5 | Vanguard FTSE Europe ETF VGK | 0.00% | 1.08M | 0.06% |
| 6 | Vanguard FTSE Developed Europe All Cap Index ETF VE.TO | 0.00% | 13.2K | 0.23% |
| 7 | Vanguard FTSE Developed All Cap ex North America Index ETF VIU.TO | 0.00% | 116.5K | 0.23% |
| 8 | Vanguard FTSE Developed All Cap ex North America Index ETF (CAD-hedged) VI.TO | 0.00% | 10.1K | 0.22% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 98.6K | 0.10% |
| 10 | Vanguard FTSE Developed All Cap ex U.S. Index ETF (CAD-hedged) VEF.TO | 0.00% | 11.9K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
24.8K
Shares Outstanding
12.43M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Matthias Schupp | Chief Executive Officer & Member of the Executive Management Board | 2M | male |
| Thomas Straumann | Founder & Vice Chairman | 292.0K | — |
| David Thoni | President of US & Member of Executive Management Board | — | male |
| Dirk W. Kirsten | Executive Officer | — | male |
| Marc Ammann | Executive Vice President of R&D and Innovation and Member of the Executive Management Board | — | male |
| Anisha Wharton | Head of Regulatory Affairs | — | female |
| Mario Della Casa | Chief Operating Officer & Member of Management Board | — | male |
| Peter Hackel | CFO & Member of Executive Management Board | — | — |
| Mareike Loch | President of EMEA & Member of Executive Management Board | — | female |
| Caroline Knoeri | Chief Human Resources Officer & Executive Management Board Member | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MED.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
